KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer.

K Laktionov, A Smolin, D Stroyakovskiy, V Moiseenko, M Dvorkin, T Andabekov, Y Cheng, B Liu, V Kozlov, S Odintsova, S Dvoretsky, A Mochalova, M Urda, T Yi, X Li, U László, V Müller, K Bogos, N Fadeeva, G Musaev, Q Liu, D Kirtbaya, J Shi, O Gladkov, M Narimanov, T Semiglazova, A Khasanova, J Chovanec, I Andrašina, A Szabová, O Rosinská, D Sudekova, P-S Zsolt, F Ran, M Sun, O Jiang, R Chen, E Zhao, C Liu, W Tan, A Pirmagomedov, E Poddubskaya, N Kislov, I Shumskaya, I Sorokina, A Zinkina-Orikhan, Yu Linkova, S Fogt, D Liaptseva, A Siliutina, O Basova, F Kryukov

Eur J Cancer 217 115255

PMID39879779
PMCID-
DOI10.1016/j.ejca.2025.115255
发表日期2025-01-29
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:未获得 PubMed/PMC 可审查 Figure,无法核实 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: Prolgolimab is an IgG1 anti-PD-1 monoclonal antibody with the Fc-silencing 'LALA' mutation. The phase III DOMAJOR study assessed efficacy and safety of prolgolimab in combination with pemetrexed and platinum-based chemotherapy vs placebo in combination with pemetrexed and platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC). METHODS: 292 patients with advanced non-squamous NSCLC were randomized 1:1 to receive 4 cycles of pemetrexed, platinum-based drug and either prolgolimab (3 mg/kg Q3W) or placebo followed by prolgolimab/placebo with pemetrexed until disease progression or toxicity (≤36 months). The primary endpoint was overall survival (OS). RESULTS: After a median follow-up of 18 months, the median OS was not reached (95 % CI, 22.28 - NA) in the prolgolimab-combination group vs 14.6 months (95 % CI, 11.73 - 19.15) in the placebo-combination group (HR, 0.51; 95 % CI, 0.35 - 0.73, p = 0.0001). The OS improvement was independent of PD-L1 status. Median progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) was 7.7 months in the prolgolimab-combination group and 5.5 months in the placebo-combination group (HR, 0.65; 95 % CI, 0.49 - 0.85, p = 0.0004). The only adverse events that were reported in at least 10 % of the patients that were significantly more frequent in the prolgolimab-combination group were blood creatinine increased and dyspnoea. CONCLUSION: Among patients with advanced NSCLC the addition of prolgolimab to pemetrexed and a platinum-based drug increased OS and PFS, with no new safety concerns. This benefit was retained in patients with PD-L1 negative tumors. (ClinicalTrials.gov, NCT03912389).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。